Skip to main content

Advertisement

Table 2 Relative expression of the htid splice forms L, I, S and the HER-2 transcript in human breast cancer

From: In vivo evidence of htid suppressive activity on ErbB-2 in breast cancers over expressing the receptor

Sample 1 2 3 4 5 6 7 8
T/N/M/G status 2/1/1/3 1/0/0/3 4/1/x/2 3/1/1/3 2/1/1/3 2/1/1/3 1/2/0/2 2/1/0/3
Target gene          
h tid- L ΔCt 4,68 3,32 2,77 5,81 4,38 4.08 2,08 2,57
  ΔΔCt 0,94 -0,43 -0,98 2,07 0,64 0,34 -1,66 -1,18
  2 -ΔΔ Ct 0,52 1,35 1,97 0,24 0,64 0,79 3,16 2,27
Rel. expression (%) 52 135 197 24 64 79 316 227
h tid- I ΔCt 1,55 2,99 2,21 2,89 0,77 0,82 1,88 0,35
  ΔΔCt 0,54 1,28 1,20 1,88 -0,24 -0,19 0,87 -0,66
  2 -ΔΔ Ct 0,69 0,41 0,44 0,27 1,18 1,14 0,55 1,58
Rel. expression (%) 69 41 44 27 118 114 55 158
h tid- S ΔCt 14,55 15,61 15,34 15,84 13,39 13,43 14,75 14,22
  ΔΔCt -0,4 0,67 0,4 0,90 -1,55 -1,51 -0,19 -0,72
  2 --ΔΔ Ct 1,32 0,63 0,76 0,54 2,93 2,85 1,14 1,65
Rel. expression (%) 132 63 76 54 293 285 114 165
HER- 2 ΔCt 1,63 0,44 0,29 -0,11 0,60 -0,69 -1,11 -2,37
  ΔΔCt 3,95 2,76 2,61 2,21 1,72 1,63 1,21 -0,05
  2 -ΔΔ Ct 0,06 0,15 0,16 0,22 0,30 0,32 0,43 1,04
Rel. expression (%) 6 15 16 22 30 32 43 104
Sample 9 10 11 12 13 14 15  
T/N/M/G status 2/0/0/2 1/x/x/2 1/2/0/3 3/1/x/3 4/2/0/3 4/2/0/3 3/4/0/3  
Target gene          
h tid- L ΔCt 3,47 3,43 4,08 0,68 3,44 3,89 2,08  
  ΔΔCt -0,28 -0,31 0,34 -3,06 -0,31 0,15 -1,66  
  2 -ΔΔ Ct 1,21 1,24 0,79 8,34 1,24 0,90 3,16  
Rel. expression (%) 121 124 79 834 124 90 316  
h tid- I ΔCt 2,40 0,06 1,77 0,37 -0,08 0,90 1,28  
  ΔΔCt 1,39 -1,06 0,76 -0,64 -1,09 0,11 0,27  
  2 -ΔΔ Ct 0,38 2,08 0,59 1,56 2,13 0,93 0,83  
Rel. expression (%) 38 208 59 156 213 93 83  
h tid- S ΔCt 15,91 13,02 13,90 13,84 13,32 17,55 13,51  
  ΔΔCt 0,97 -1,92 -1,04 -1,10 -1,62 2,61 -1,43  
  2 -ΔΔ Ct 0,51 3,80 2,06 2,14 3,07 0,16 2,70  
Rel. expression (%) 51 380 206 214 307 16 270  
HER- 2 ΔCt -2,63 -2,97 -3,00 -3,23 -3,40 -5,71 -6,31  
  ΔΔCt -0,31 -0,65 -0,68 0,91 -1,08 -3,39 -3,99  
  2 -ΔΔ Ct 1,24 1,57 1,60 1,88 2,11 10,48 15.93  
Rel. expression (%) 124 157 160 180 211 1048 1593  
  1. The samples are sorted according to the increase of HER-2 expression. The average ΔCt values (n=3) are presented. The calculation of ΔΔCt involves substraction by the ΔCt calibrator value (normal sample), ΔΔCt = ΔCt (tumor sample) - ΔCt (normal sample). The SD of ΔΔCt is the same as the SD of the ΔCt. The ΔCt values of both the tumor and normal samples are standardized to HGPRT used as endogenous control. The values defined as increase of expression represent the relative (rel.) change/increase in expression of the defined target as compared to normal sample and are calculated as follows: 2-ΔΔCt × 100%. T, tumor extension: T1, to submucosa; T2, to muscle layer; T3, to subserosa; T4, to serosa. N, lymph node affection; M, metastasis; G, grading: G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; x, not defined.